![BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]- 190728-25-7 Cabozantinib intermediate white powder buy - large image1](https://file.echemi.com/fileManage/upload/goodpicture/20220728/3r-4s-1-benzoyl-4-phenyl-3-triethylsilyloxy-2-azetidinone-149249-91-2-taxoid-side-chain-white-powder_b20220728152119283.jpg)
![BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]- 190728-25-7 Cabozantinib intermediate white powder buy - image1](https://file.echemi.com/fileManage/upload/goodpicture/20220728/s20220728152118964.jpg "BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]- 190728-25-7 Cabozantinib intermediate white powder")
BenzenaMine, 4-[(6,7-diMethoxy-4-quinolinyl)oxy]- 190728-25-7 Cabozantinib intermediate white powder
190728-25-7
shanghai
1kg/bag
2023-03-03
calcium L-5-methyltetrahydrofolate
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
4-[(6,7-Dimethoxyquinolin-4-yl)oxy]aniline
Other Name:Benzenamine,4-[(6,7-dimethoxy-4-quinolinyl)oxy]-;4-[(6,7-Dimethoxy-4-quinolinyl)oxy]benzenamine;6,7-Dimethoxy-4-(4-aminophenoxy)quinoline;[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]amine;4-[(6,7-Dimethoxyquinolin-4-yl)oxy]aniline
CAS No.:190728-25-7
Molecular Formula:C17H16N2O3
InChIKeys:InChIKey=VXEQRXJATQUJSN-UHFFFAOYSA-N
Molecular Weight:296.32054
Exact Mass:296.32
EC Number:-0
DSSTox ID:DTXSID40469172
HScode:2933499090
Categories:
Characteristics-
PSA:
66.6
XLogP3:3
Density:1.246±0.06 g/cm3 (20 ºC 760 Torr)
Melting Point:211.0 to 215.0 °C
Boiling Point:481.8±45.0 °C(Predicted)
Flash Point:245.2±28.7 °C
Refractive Index:1.646
Hazard IdentificationClassification of the substance or mixture
Skin irritation, Category 2
Eye irritation, Category 2
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H315 Causes skin irritation
H319 Causes serious eye irritation
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P302+P352 IF ON SKIN: Wash with plenty of water/...
P321 Specific treatment (see ... on this label).
P332+P317 If skin irritation occurs: Get medical help.
P362+P364 Take off contaminated clothing and wash it before reuse.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
calcium L-5-methyltetrahydrofolate
-
Location:
No.111,Qinxin Rd,Donggang Town,Xishan Dist,Wuxi,China.
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A
-
Average lead Time:
300
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
101-200
-
Year of Establishment:
2004
-
Certifications:
KOSEHR
Wuxi Taxus Pharmaceutical Co.,Ltd was established in 2004,and a bio-pharmaceutical company under the HODO Group which is the top 500 private enterprises . It is mainly engaged in the research, development, production and sales of paclitaxel-based anti-tumor drugs. The complete industrial chain was established,from the cultivation of yew resources to the processing of yew branches and leaves, paclitaxel primary products, paclitaxel series of raw materials and intermediates to preparations . Products include paclitaxel, docetaxel, cabazitaxel, 10-DAB, oxaliplatin, dresian hydrochloride, allopurinol, L-5-methylfolate, L-5-methylfolate, etc. API, and paclitaxel injection.
The company has strong technical strength. In 2018, the company established the Hongdoushan International Pharmaceutical Research and Development Company in New York, focusing on the research and development and introduction of anticancer drugs. At present, the Hongdoushan research and development center hires the Doctor returned from abroad to lead the research and development of new products, and currently has more than 30 senior engineers. What’s more, the R&D Center has established close cooperative relations with Jiangsu Academy of Agricultural Sciences, Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tsinghua University, and foreign research institutes.
The company's paclitaxel API has obtained the US DMF registration number (25759), and is registered in Korea, India, Iran, Russia, Belarus and other countries. It is sold at home and abroad, mainly exported to India, South America, Russia, Egypt and other countries and regions,and praised
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product